Previous 10 | Next 10 |
2023-08-09 14:48:51 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q2 GAAP EPS of -$0.52. Revenue of $2.2M. Total revenue for the three-month period ended June 30, 2023 was $2.2 million as compared with ($0.2 million) for the same period in 2022, representing an i...
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025 Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) ...
Highlights progress, recent developments and upcoming key milestones C ompany c ontinu es to build growing body of data across pipeline , a dvancing towards first in human studies S trong financial position with cash projected to fund op...
Live moderated video webcast on Thursday, July 13 th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company de...
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all ite...
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, t...
2023-05-09 17:46:49 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q1 GAAP EPS of -$0.88. Revenue of $2.1M (+40.0% Y/Y). The Company had $46.6 million in cash and cash equivalents at March 31, 2023. For further details see: Aeterna Zentaris GAAP EPS of -...
– Ended the quarter with $ 46 . 6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerat e recruitment for DETECT trial A ctively seeking alternate development and commercializatio...
2023-04-05 08:48:13 ET The shares of nano-cap biotech Aeterna Zentaris ( NASDAQ: AEZS ) lost ~13% pre-market Wednesday after announcing a temporary halt to U.S. sales of its lead product Macrilen (macimorelin), effective May 23, 2023. The temporary move follows last year...
U . S . sales of Macrile n ® for adult use to be temporarily discontinued as of May 23, 2023 , while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen ...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...